Global Vertigo Market: Industry Analysis & Outlook (2017-2021)
Vertigo is a medical condition where a person feels as if they or the objects around them are moving when they are not. Often it feels like a spinning or swaying movement. This may be associated with nausea, vomiting, sweating, or difficulties walking. It is typically worsened when the head is moved. Vertigo is the most common type of dizziness. The causes for vertigo can be divided into two categories: Peripheral and Central. Peripheral is linked to the inner ear whereas central is linked to problems in Central Nervous System.
Peripheral vertigo can be further segmented into five major categories: Benign paroxysmal positional vertigo (BPPV), Acute Unilateral Vestibulopathy, Meniere’s disease and Vestibular Schwannoma. Amongst all the stated indication, Meniere’s disease represents the largest growth opportunity for the market players with its continuously rising incidence.
Growth of global vertigo market is expected to be driven by factors such as rising incidence and prevalence of peripheral etiologies of vertigo, increasing geriatric population, growing healthcare expenditure and improving disposable income. Further, the market growth could be hindered by side effects of currently prescribed medication, the high cost of treatment and tedious drug approval process. The key trends for the market include extensive research & development and different approaches being adopted by drug manufacturers in order to target vertigo.
A key drug Otividex, which is currently in third phase of clinical trials and is being developed by Otonomy Inc., is discussed in the report. The drug is easier to use and provides a higher and sustained concentration of dexamethasone relative to existing injections. Further, it is anticipated to provide a well-accepted treatment option for Meniere’s Disease, if successfully developed.
The report “Global Vertigo Market: Industry Analysis & Outlook (2017-2021)” analyzes the development of this market, with focus on Europe and US regions. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players involved in the development of breakthrough drug therapy for vertigo: Auris Medical Holding AG., Sensorion SA, Otonomy, Inc. and Sound Pharmaceuticals, Inc. are being profiled along with their key financials and strategies for growth.
Peripheral vertigo can be further segmented into five major categories: Benign paroxysmal positional vertigo (BPPV), Acute Unilateral Vestibulopathy, Meniere’s disease and Vestibular Schwannoma. Amongst all the stated indication, Meniere’s disease represents the largest growth opportunity for the market players with its continuously rising incidence.
Growth of global vertigo market is expected to be driven by factors such as rising incidence and prevalence of peripheral etiologies of vertigo, increasing geriatric population, growing healthcare expenditure and improving disposable income. Further, the market growth could be hindered by side effects of currently prescribed medication, the high cost of treatment and tedious drug approval process. The key trends for the market include extensive research & development and different approaches being adopted by drug manufacturers in order to target vertigo.
A key drug Otividex, which is currently in third phase of clinical trials and is being developed by Otonomy Inc., is discussed in the report. The drug is easier to use and provides a higher and sustained concentration of dexamethasone relative to existing injections. Further, it is anticipated to provide a well-accepted treatment option for Meniere’s Disease, if successfully developed.
The report “Global Vertigo Market: Industry Analysis & Outlook (2017-2021)” analyzes the development of this market, with focus on Europe and US regions. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players involved in the development of breakthrough drug therapy for vertigo: Auris Medical Holding AG., Sensorion SA, Otonomy, Inc. and Sound Pharmaceuticals, Inc. are being profiled along with their key financials and strategies for growth.
1. INTRODUCTION
1.1 Vertigo
1.2 Causes & Types
1.3 Diagnosis & Treatment
2. GLOBAL VERTIGO MARKET
2.1 Global Recurrent Vestibular Vertigo Patient Forecast
2.2 Global Treatable Vertigo Patient by Indication
2.3 Global Treatable Vertigo Patient by Region
2.4 Global Treatable Vertigo Episodes by Region
2.5 Global Meniere’s disease Market
2.5.1 Global Meniere’s disease Patient Forecast
2.5.2 Global Meniere’s disease Patient by Region
2.5.3 Global Otividex Drug Sales Forecast
3. REGIONAL MARKET
3.1 Europe
3.1.1 Europe Recurrent Vestibular Vertigo Patient Forecast
3.1.2 Europe Treatable Vertigo Patient by Indication
3.1.3 Europe Meniere’s Disease Patient Forecast
3.1.4 Europe Otividex Drug Sales Forecast
3.2 The US
3.2.1 The US Recurrent Vestibular Vertigo Patient Forecast
3.2.2 The US Treatable Vertigo Patient by Indication
3.2.3 The US Meniere’s disease Patient Forecast
3.2.4 The US Meniere’s Disease Patient Eligible for Steroid Injections
3.2.5 The US Otividex Sales Forecast
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Growing Patient Population
4.1.2 Rising Geriatric Population
4.1.3 Increasing Healthcare Expenditure
4.1.4 Rising Disposable Income
4.2 Key Trends & Development
4.2.1 Extensive R&D Expenditure
4.2.2 Players Adopting Different Approaches for Drug Mechanism
4.3 Key Challenges
4.3.1 Hasty Drug Approval Process
4.3.2 Side Effects of the Current Therapies
4.3.3 High Cost
5. COMPETITIVE LANDSCAPE
5.1 Global Vertigo Market
5.1.1 Market Cap. Comparison by Companies
5.1.2 Product Comparison by Companies
6. COMPANY PROFILES
6.1 Auris Medical Holding AG
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Sensorion SA
6.2.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategy
6.3 Otonomy, Inc.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategy
6.4 Sound Pharmaceuticals, Inc.
6.4.1 Business Overview
6.4.2 Business Strategy
List of Charts
Diagnosis & Treatment Flowchart for Vertigo/Dizziness
Global Recurrent Vestibular Vertigo Patient Forecast (2016-2021)
Global Treatable Vertigo Patient by Indication (2016)
Global Treatable Vertigo Patient by Region (2016)
Global Treatable Vertigo Episodes by Region (2016)
Global Meniere’s disease Patient Forecast (2016-2021)
Global Meniere’s disease Patient by Region (2016)
Global Otividex Drug Sales Forecast (2020-2025)
Europe Recurrent Vestibular Vertigo Patient Forecast (2016-2021)
Europe Treatable Vertigo Patient by Indication (2016)
Europe Meniere’s Disease Patient Forecast (2016-2021)
Europe Otividex Drug Sales Forecast (2022-2025)
The US Recurrent Vestibular Vertigo Patient Forecast (2016-2021)
The US Treatable Vertigo Patient by Indication (2016)
The US Meniere’s Disease Patient Forecast (2016-2021)
The US Meniere’s Disease Patient Eligible for Steroid Injections (2016-2021)
The US Otividex Sales Forecast (2020-2025)
Global Population above 64 Years (2012-2016)
Global Healthcare Expenditure (2012-2016)
Global GDP Per Capita (2012-2016)
R&D Expenditure Incurred by Companies (2016)
Drug Approval Process
Auris Medical Holding AG Net Loss (2012-2016)
Auris Medical Holding AG R&D Expenditure (2012-2016)
Sensorion SA Operating Income & Net Loss (2014-2016)
Sensorion SA R&D Expenditure (2014-2016)
Otonomy, Inc. Net Sales and Net Loss (2012-2016)
Otonomy, Inc. R&D Expenditure (2014-2016)
1.1 Vertigo
1.2 Causes & Types
1.3 Diagnosis & Treatment
2. GLOBAL VERTIGO MARKET
2.1 Global Recurrent Vestibular Vertigo Patient Forecast
2.2 Global Treatable Vertigo Patient by Indication
2.3 Global Treatable Vertigo Patient by Region
2.4 Global Treatable Vertigo Episodes by Region
2.5 Global Meniere’s disease Market
2.5.1 Global Meniere’s disease Patient Forecast
2.5.2 Global Meniere’s disease Patient by Region
2.5.3 Global Otividex Drug Sales Forecast
3. REGIONAL MARKET
3.1 Europe
3.1.1 Europe Recurrent Vestibular Vertigo Patient Forecast
3.1.2 Europe Treatable Vertigo Patient by Indication
3.1.3 Europe Meniere’s Disease Patient Forecast
3.1.4 Europe Otividex Drug Sales Forecast
3.2 The US
3.2.1 The US Recurrent Vestibular Vertigo Patient Forecast
3.2.2 The US Treatable Vertigo Patient by Indication
3.2.3 The US Meniere’s disease Patient Forecast
3.2.4 The US Meniere’s Disease Patient Eligible for Steroid Injections
3.2.5 The US Otividex Sales Forecast
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Growing Patient Population
4.1.2 Rising Geriatric Population
4.1.3 Increasing Healthcare Expenditure
4.1.4 Rising Disposable Income
4.2 Key Trends & Development
4.2.1 Extensive R&D Expenditure
4.2.2 Players Adopting Different Approaches for Drug Mechanism
4.3 Key Challenges
4.3.1 Hasty Drug Approval Process
4.3.2 Side Effects of the Current Therapies
4.3.3 High Cost
5. COMPETITIVE LANDSCAPE
5.1 Global Vertigo Market
5.1.1 Market Cap. Comparison by Companies
5.1.2 Product Comparison by Companies
6. COMPANY PROFILES
6.1 Auris Medical Holding AG
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Sensorion SA
6.2.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategy
6.3 Otonomy, Inc.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategy
6.4 Sound Pharmaceuticals, Inc.
6.4.1 Business Overview
6.4.2 Business Strategy
List of Charts
Diagnosis & Treatment Flowchart for Vertigo/Dizziness
Global Recurrent Vestibular Vertigo Patient Forecast (2016-2021)
Global Treatable Vertigo Patient by Indication (2016)
Global Treatable Vertigo Patient by Region (2016)
Global Treatable Vertigo Episodes by Region (2016)
Global Meniere’s disease Patient Forecast (2016-2021)
Global Meniere’s disease Patient by Region (2016)
Global Otividex Drug Sales Forecast (2020-2025)
Europe Recurrent Vestibular Vertigo Patient Forecast (2016-2021)
Europe Treatable Vertigo Patient by Indication (2016)
Europe Meniere’s Disease Patient Forecast (2016-2021)
Europe Otividex Drug Sales Forecast (2022-2025)
The US Recurrent Vestibular Vertigo Patient Forecast (2016-2021)
The US Treatable Vertigo Patient by Indication (2016)
The US Meniere’s Disease Patient Forecast (2016-2021)
The US Meniere’s Disease Patient Eligible for Steroid Injections (2016-2021)
The US Otividex Sales Forecast (2020-2025)
Global Population above 64 Years (2012-2016)
Global Healthcare Expenditure (2012-2016)
Global GDP Per Capita (2012-2016)
R&D Expenditure Incurred by Companies (2016)
Drug Approval Process
Auris Medical Holding AG Net Loss (2012-2016)
Auris Medical Holding AG R&D Expenditure (2012-2016)
Sensorion SA Operating Income & Net Loss (2014-2016)
Sensorion SA R&D Expenditure (2014-2016)
Otonomy, Inc. Net Sales and Net Loss (2012-2016)
Otonomy, Inc. R&D Expenditure (2014-2016)
LIST OF TABLES
Common Causes of Peripheral and Central Vestibular Disorders
Incidence and Prevalence of Peripheral Etiologies of Vertigo per 100,000 (2016)
Vertigo Drugs in Development (2016)
Current Treatments Therapies for Vertigo & Side Effects
Market Cap. Comparison by Companies (2016)
Product Comparison by Companies (2016)
Auris’s Key Drugs Under Pipeline (2017)
Sensorion’s Key Drug Pipeline (2017)
Otonomy’s Key Drugs Under Pipeline (2017)
Sound’s Key Drug Pipeline (2017)
Common Causes of Peripheral and Central Vestibular Disorders
Incidence and Prevalence of Peripheral Etiologies of Vertigo per 100,000 (2016)
Vertigo Drugs in Development (2016)
Current Treatments Therapies for Vertigo & Side Effects
Market Cap. Comparison by Companies (2016)
Product Comparison by Companies (2016)
Auris’s Key Drugs Under Pipeline (2017)
Sensorion’s Key Drug Pipeline (2017)
Otonomy’s Key Drugs Under Pipeline (2017)
Sound’s Key Drug Pipeline (2017)
